These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11522269)

  • 1. Biochemical markers in breast cancer: which ones are clinically useful?
    Duffy MJ
    Clin Biochem; 2001 Jul; 34(5):347-52. PubMed ID: 11522269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intra-tissue biological markers in cancers of the breast: current assessment].
    Romain S; Spyratos F; Goussard J; Magdelenat H; Martin PM
    Arch Anat Cytol Pathol; 1994; 42(5):251-61. PubMed ID: 7872816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor markers in breast cancer--evaluation of their clinical usefulness.
    Marić P; Ozretić P; Levanat S; Oresković S; Antunac K; Beketić-Oresković L
    Coll Antropol; 2011 Mar; 35(1):241-7. PubMed ID: 21661378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Contribution of biology to the therapeutic decision: cancer of the breast in 1995].
    Chinot O; Romain S; Martin PM
    Bull Cancer Radiother; 1995; 82(2):225-37. PubMed ID: 7546893
    [No Abstract]   [Full Text] [Related]  

  • 5. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
    Harris L; Fritsche H; Mennel R; Norton L; Ravdin P; Taube S; Somerfield MR; Hayes DF; Bast RC;
    J Clin Oncol; 2007 Nov; 25(33):5287-312. PubMed ID: 17954709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive markers in breast and other cancers: a review.
    Duffy MJ
    Clin Chem; 2005 Mar; 51(3):494-503. PubMed ID: 15637130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
    Duffy MJ; Harbeck N; Nap M; Molina R; Nicolini A; Senkus E; Cardoso F
    Eur J Cancer; 2017 Apr; 75():284-298. PubMed ID: 28259011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic factors in breast cancer patients].
    Roisman I; Peretz T; Reznick AZ; Lifshitz I; Bitterman A; Fares F; Toledano H; Barzilay A; Durst AL
    Harefuah; 1996 May; 130(10):693-9. PubMed ID: 8794662
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
    Dowsett M; Dunbier AK
    Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
    Molina R; Barak V; van Dalen A; Duffy MJ; Einarsson R; Gion M; Goike H; Lamerz R; Nap M; Sölétormos G; Stieber P
    Tumour Biol; 2005; 26(6):281-93. PubMed ID: 16254457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular testing in breast cancer.
    Paoletti C; Hayes DF
    Annu Rev Med; 2014; 65():95-110. PubMed ID: 24422569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validated biomarkers: The key to precision treatment in patients with breast cancer.
    Duffy MJ; O'Donovan N; McDermott E; Crown J
    Breast; 2016 Oct; 29():192-201. PubMed ID: 27521224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.
    Le Goff JM; Lavayssière L; Rouëssé J; Spyratos F
    Anticancer Res; 2000; 20(3B):2213-8. PubMed ID: 10928180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic and predictive factors in breast cancer].
    Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
    Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer.
    Brennan M; Lim B
    Adv Exp Med Biol; 2015; 867():327-37. PubMed ID: 26530375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
    Schmitt M; Thomssen C; Ulm K; Seiderer A; Harbeck N; Höfler H; Jänicke F; Graeff H
    Br J Cancer; 1997; 76(3):306-11. PubMed ID: 9252196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.